Advertisement Iverson, Johns Hopkins in molecular diagnostics test license agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Iverson, Johns Hopkins in molecular diagnostics test license agreement

Iverson Genetic Diagnostics has entered into a licensing agreement with Johns Hopkins University School of Medicine for a molecular diagnostics test, designed to help physicians to assess cardiovascular risk in men and women, and infertility risk in women.

Under the agreement, Iverson gained marketing rights for the product which determines the healthy cholesterol fraction, HDL, and its partner protein, scavenger receptor class B type I (SR-BI).

Studies conducted by Annabelle Rodriguez-Oquendo, at John Hopkins University School of Medicine, suggested that mutations within the SR-BI gene (SCARB1) is associated with heart disease risk in men and women as well as hormonal and fertility problems in women.

Iverson Genetic Diagnostics board of directors member and Institute for Systems Biology co-founder Leroy Hood said, "The importance of finding gene variants that affect the metabolism of cholesterol, especially the healthy fraction, and hormones–hence causing disease–is incredibly important for personalized medicine."

Iverson Genetic Diagnostics CEO Dean Sproles said, "We are very pleased to collaborate with Johns Hopkins University School of Medicine on this product and look forward to including the new SR-BI test in the Iverson’s Physician’s LogicTM portfolio later this year."